Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered form

Patent metadata

Field	Value
Publication number	US-11033619-B2
Application number	US-201816005466-A
Country	US
Kind code	B2
Filing date	Jun 11, 2018
Priority date	Nov 26, 2014
Publication date	Jun 15, 2021
Grant date	Jun 15, 2021

Abstract

The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

First claim

The invention claimed is:

1. A method for immunotherapy of a patient in need thereof, comprising administering a combination of immune effector cells and non-target hematopoietic cells to the patient, comprising:
(a) obtaining a population of immune effector cells,
wherein the immune effector cells are derived from cells of the patient or an allogeneic effector cell donor and modified to express a chimeric recombinant antigen-recognizing receptor (CAR) that binds an extracellular epitope of a target antigen,
wherein the target antigen is a cell surface antigen expressed on target cells and on cells of a non-target hematopoietic cell subpopulation of the patient;
(b) obtaining cells of the non-target hematopoietic cell subpopulation from the patient or an allogeneic cell donor;
(c) producing a progeny cell population from the non-target hematopoietic cell subpopulation by a process that comprises gene-editing the cells obtained in step (b) and obtaining progeny of the gene-edited cells, wherein said gene-editing results in expression of an altered form of the target antigen by cells of the progeny cell population,
wherein the altered form of the target antigen has at least one amino acid substitution or deletion in the extracellular epitope bound by the CAR, wherein the CAR has lower binding affinity to the altered form of the target antigen compared with the target antigen expressed on the immune effector cells obtained in step (a);
(d) administering the immune effector cells and cells of the progeny cell population to the patient.

2. The method of claim 1 wherein the immune effector cells are CAR T cells produced by a process that comprises genetically modifying T cells obtained in step (a).

3. The method of claim 1 wherein the immune effector cells are CAR NK cells produced by a process that comprises genetically modifying NK cells obtained in step (a).

4. The method of claim 1 wherein the target cells are cancer cells that express the target antigen.

5. The method of claim 1 wherein the immune effector cells are administered to the subject before or after the cells of the progeny cell population are administered.

6. The method of claim 1 wherein the extracellular domain of the target antigen is modified by one amino acid substitution or deletion to produce the altered form of the target antigen.

7. The method of claim 1 wherein the extracellular domain of the target antigen is modified by two amino acid substitutions or deletions to produce the altered form of the target antigen.

8. The method of claim 1 wherein the extracellular domain of the target antigen is modified by three amino acid substitutions or deletions to produce the altered form of the target antigen.

9. The method of claim 1 wherein the extracellular domain of the target antigen is modified by five amino acid substitutions or deletions to produce the altered form of the target antigen.

10. The method of claim 1 wherein the extracellular domain of the target antigen is modified by a deletion of more than five amino acid substitutions or deletions to produce the altered form of the target antigen.

11. The method of claim 1 wherein the target antigen is CD11a, CD18, CD19, CD20, CD31, CD34, CD44, CD45, CD47, CD51, CD58, CD59, CD63, CD97, CD99, CD100, CD102, CD123, CD127, CD133, CD135, CD157, CD172b, CD217, CD300a, CD305, CD317 or CD321.

Assignees

• Miltenyi Biotec Gmbh
• Miltenyi Biotec Bv & Co Kg

Inventors

• Lutteropp Michael
• Richter Anne
• Kaiser Andrew
• Assenmacher Mario
• Miltenyi Stefan

Classifications

• A61K38/1774 Primary

  Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules) · CPC title

• A61K40/4221

  CD20 · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2039/5156

  expressing foreign proteins · CPC title